Given the limited sensitivity and potential overlap with other mechanisms and diagnoses, core AD biomarkers—amyloid and tau—are primarily recommended for evaluating symptomatic individuals rather than cognitively unimpaired populations [13]. This evidence concerns the gene MAPT and Alzheimer disease.